Last reviewed · How we verify
PK101-002
PK101-002 is a small molecule that targets the HIF-1α pathway.
PK101-002 is a small molecule that targets the HIF-1α pathway. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | PK101-002 |
|---|---|
| Also known as | A |
| Sponsor | PMG Pharm Co., Ltd |
| Drug class | HIF-1α inhibitor |
| Target | HIF-1α |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PK101-002 works by inhibiting the HIF-1α protein, which is involved in the regulation of cellular responses to hypoxia. This inhibition leads to a decrease in the production of angiogenic factors, resulting in anti-tumor effects.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis (PHASE3)
- Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs (PHASE1)
- Drug-Drug Interaction Between PK101-001 and PK101-002 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PK101-002 CI brief — competitive landscape report
- PK101-002 updates RSS · CI watch RSS
- PMG Pharm Co., Ltd portfolio CI